-$0.29 Earnings Per Share Expected for Osmotica Pharmaceuticals plc (NASDAQ:OSMT) This Quarter

Brokerages expect that Osmotica Pharmaceuticals plc (NASDAQ:OSMT) will report earnings of ($0.29) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Osmotica Pharmaceuticals’ earnings, with estimates ranging from ($0.31) to ($0.26). Osmotica Pharmaceuticals posted earnings of ($0.26) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.5%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, March 29th.

On average, analysts expect that Osmotica Pharmaceuticals will report full year earnings of ($1.19) per share for the current year, with EPS estimates ranging from ($1.30) to ($0.98). For the next year, analysts anticipate that the company will post earnings of ($0.76) per share, with EPS estimates ranging from ($0.92) to ($0.63). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Monday, November 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.06). Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative return on equity of 81.23%. The business had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $2.39 million. During the same quarter last year, the business earned ($0.14) EPS.

A number of brokerages have issued reports on OSMT. HC Wainwright began coverage on Osmotica Pharmaceuticals in a research note on Thursday, December 23rd. They issued a “buy” rating and a $5.00 target price for the company. Jefferies Financial Group assumed coverage on Osmotica Pharmaceuticals in a research note on Tuesday, November 9th. They issued a “buy” rating for the company. Zacks Investment Research downgraded Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, December 9th. Truist Securities decreased their target price on shares of Osmotica Pharmaceuticals from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, October 11th. Finally, Truist dropped their price target on shares of Osmotica Pharmaceuticals from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, October 11th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, Osmotica Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $5.80.

In other Osmotica Pharmaceuticals news, COO James Schaub bought 93,800 shares of Osmotica Pharmaceuticals stock in a transaction on Thursday, December 16th. The shares were bought at an average cost of $1.07 per share, for a total transaction of $100,366.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 5.22% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Osmotica Pharmaceuticals by 30.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 74,778 shares of the company’s stock worth $220,000 after acquiring an additional 17,553 shares in the last quarter. Nations Financial Group Inc. IA ADV acquired a new stake in Osmotica Pharmaceuticals during the 3rd quarter worth $37,000. Deutsche Bank AG raised its stake in Osmotica Pharmaceuticals by 34.3% during the 3rd quarter. Deutsche Bank AG now owns 71,103 shares of the company’s stock worth $210,000 after acquiring an additional 18,149 shares in the last quarter. Millennium Management LLC acquired a new stake in Osmotica Pharmaceuticals during the 2nd quarter worth $482,000. Finally, Credit Suisse AG acquired a new stake in Osmotica Pharmaceuticals during the 2nd quarter worth $84,000. Institutional investors and hedge funds own 46.18% of the company’s stock.

OSMT stock remained flat at $$1.13 during midday trading on Friday. The company’s stock had a trading volume of 305,185 shares, compared to its average volume of 406,709. The firm has a 50-day moving average price of $1.30 and a two-hundred day moving average price of $2.42. Osmotica Pharmaceuticals has a 12 month low of $0.98 and a 12 month high of $4.95.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women’s health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs.

See Also: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.